Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine announced a proposed $350 million underwritten public offering of common stock and pre-funded warrants, with a 30-day underwriter option for up to $52.5 million more. Proceeds are earmarked for clinical development, potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and general corporate purposes.
Key figures
- Deal Value Usd
- 350000000
- Securities
- common stock and pre-funded warrants
- Greenshoe option
- $52.5 million additional shares (30-day underwriter option)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.